Aquatic Capital Management LLC lowered its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 20.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 164,842 shares of the company's stock after selling 42,358 shares during the quarter. Aquatic Capital Management LLC owned about 0.13% of Guardant Health worth $5,036,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of GH. Norges Bank acquired a new position in Guardant Health during the 4th quarter worth about $36,438,000. Lord Abbett & CO. LLC acquired a new stake in shares of Guardant Health during the third quarter worth about $15,624,000. Vanguard Group Inc. lifted its position in shares of Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares in the last quarter. Eversept Partners LP purchased a new position in shares of Guardant Health in the fourth quarter valued at approximately $8,433,000. Finally, Blue Water Life Science Advisors LP grew its holdings in shares of Guardant Health by 53.9% in the fourth quarter. Blue Water Life Science Advisors LP now owns 694,047 shares of the company's stock valued at $21,203,000 after purchasing an additional 243,000 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
Guardant Health Price Performance
Guardant Health stock opened at $48.30 on Friday. The stock has a market capitalization of $5.96 billion, a P/E ratio of -13.57 and a beta of 1.45. Guardant Health, Inc. has a 12-month low of $17.52 and a 12-month high of $50.89. The firm's 50-day moving average is $43.37 and its two-hundred day moving average is $37.30.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the stock. Scotiabank increased their target price on shares of Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Piper Sandler increased their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus increased their price target on Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, The Goldman Sachs Group boosted their price objective on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $49.00.
View Our Latest Stock Analysis on GH
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Recommended Stories
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
